BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21057536)

  • 1. Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.
    Preston RS; Philp A; Claessens T; Gijezen L; Dydensborg AB; Dunlop EA; Harper KT; Brinkhuizen T; Menko FH; Davies DM; Land SC; Pause A; Baar K; van Steensel MA; Tee AR
    Oncogene; 2011 Mar; 30(10):1159-73. PubMed ID: 21057536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the Birt-Hogg-Dubé gene product folliculin induces longevity in a hypoxia-inducible factor-dependent manner.
    Gharbi H; Fabretti F; Bharill P; Rinschen MM; Brinkkötter S; Frommolt P; Burst V; Schermer B; Benzing T; Müller RU
    Aging Cell; 2013 Aug; 12(4):593-603. PubMed ID: 23566034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
    Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
    Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folliculin deficient renal cancer cells show higher radiosensitivity through autophagic cell death.
    Zhang Q; Si S; Schoen S; Jin XB; Chen J; Wu G
    J Urol; 2014 Jun; 191(6):1880-8. PubMed ID: 24434776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous germline FLCN mutation in Birt-Hogg-Dubé syndrome with bilateral renal hybrid oncocytic/chromophobe tumor and unilateral renal chromophobe cell carcinoma: a case report.
    Li J; Liu F; Liu X; Hu Y; Liu Z; Shen Y; Wan J
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2319-2325. PubMed ID: 36258004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical characterization of renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Iribe Y; Kuroda N; Nagashima Y; Yao M; Tanaka R; Gotoda H; Kawakami F; Imamura Y; Nakamura Y; Ando M; Araki A; Matsushima J; Nakatani Y; Furuya M
    Pathol Int; 2015 Mar; 65(3):126-32. PubMed ID: 25597876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.
    Tee AR; Pause A
    Fam Cancer; 2013 Sep; 12(3):367-72. PubMed ID: 23096221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.
    Napolitano G; Di Malta C; Esposito A; de Araujo MEG; Pece S; Bertalot G; Matarese M; Benedetti V; Zampelli A; Stasyk T; Siciliano D; Venuta A; Cesana M; Vilardo C; Nusco E; Monfregola J; Calcagnì A; Di Fiore PP; Huber LA; Ballabio A
    Nature; 2020 Sep; 585(7826):597-602. PubMed ID: 32612235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study.
    Benusiglio PR; Giraud S; Deveaux S; Méjean A; Correas JM; Joly D; Timsit MO; Ferlicot S; Verkarre V; Abadie C; Chauveau D; Leroux D; Avril MF; Cordier JF; Richard S;
    Orphanet J Rare Dis; 2014 Oct; 9():163. PubMed ID: 25519458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
    Murakami T; Sano F; Huang Y; Komiya A; Baba M; Osada Y; Nagashima Y; Kondo K; Nakaigawa N; Miura T; Kubota Y; Yao M; Kishida T
    J Pathol; 2007 Apr; 211(5):524-531. PubMed ID: 17323425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
    Liu MY; Poellinger L; Walker CL
    Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.